How has the Zimbabwe mycobacterial culture and drug sensitivity testing system among re-treatment tuberculosis patients functioned during the scale-up of the Xpert MTB/RIF assay?

Hdl Handle:
http://hdl.handle.net/10144/619255
Title:
How has the Zimbabwe mycobacterial culture and drug sensitivity testing system among re-treatment tuberculosis patients functioned during the scale-up of the Xpert MTB/RIF assay?
Authors:
Timire, C; Takarinda, KC; Harries, AD; Mutunzi, H; Manyame-Murwira, B; Kumar, AMV; Sandy, C
Journal:
Transactions of the Royal Society of Tropical Medicine and Hygiene
Abstract:
In Zimbabwe, while the Xpert MTB/RIF assay is being used for diagnosing tuberculosis and rifampicin-resistance, re-treatment tuberculosis (TB) patients are still expected to have culture and drug sensitivity testing (CDST) performed at national reference laboratories for confirmation. The study aim was to document the Xpert MTB/RIF assay scale-up and assess how the CDST system functioned for re-treatment TB patients.
Publisher:
Oxford University Press
Issue Date:
1-Jun-2018
URI:
http://hdl.handle.net/10144/619255
DOI:
10.1093/trstmh/try054
PubMed ID:
29992299
Submitted date:
2018-07-17
Language:
en
ISSN:
1878-3503
Appears in Collections:
Operational Research Courses

Full metadata record

DC FieldValue Language
dc.contributor.authorTimire, Cen
dc.contributor.authorTakarinda, KCen
dc.contributor.authorHarries, ADen
dc.contributor.authorMutunzi, Hen
dc.contributor.authorManyame-Murwira, Ben
dc.contributor.authorKumar, AMVen
dc.contributor.authorSandy, Cen
dc.date.accessioned2018-08-08T16:23:12Z-
dc.date.available2018-08-08T16:23:12Z-
dc.date.issued2018-06-01-
dc.date.submitted2018-07-17-
dc.identifier.citationHow has the Zimbabwe mycobacterial culture and drug sensitivity testing system among re-treatment tuberculosis patients functioned during the scale-up of the Xpert MTB/RIF assay? 2018, 112 (6):285-293 Trans. R. Soc. Trop. Med. Hyg.en
dc.identifier.issn1878-3503-
dc.identifier.pmid29992299-
dc.identifier.doi10.1093/trstmh/try054-
dc.identifier.urihttp://hdl.handle.net/10144/619255-
dc.description.abstractIn Zimbabwe, while the Xpert MTB/RIF assay is being used for diagnosing tuberculosis and rifampicin-resistance, re-treatment tuberculosis (TB) patients are still expected to have culture and drug sensitivity testing (CDST) performed at national reference laboratories for confirmation. The study aim was to document the Xpert MTB/RIF assay scale-up and assess how the CDST system functioned for re-treatment TB patients.en
dc.language.isoenen
dc.publisherOxford University Pressen
dc.rightsPublished by Elsevier Archived on this site with the kind permission of Elsevier Ltd. ([url]http://www.sciencedirect.com/science/journal/00359203[/url]) and the Royal Society of Tropical Medicine and Hygiene ([url]http://www.rstmh.org/transactions.asp[/url])en
dc.titleHow has the Zimbabwe mycobacterial culture and drug sensitivity testing system among re-treatment tuberculosis patients functioned during the scale-up of the Xpert MTB/RIF assay?en
dc.identifier.journalTransactions of the Royal Society of Tropical Medicine and Hygieneen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.